ESR2: Vasileios Fougiaxis
ESR3: Evgenia-Galateia Georgaki
ESR4: Martha - Spyridoula Nikopaschou
ESR5: Shami Ãlvarez Mourid
- Effect of Modulation of ERAP1 activity in antigen processing and presentation
- University of Southampton - "Cancer Sciences Unit" Lab
ESR6: Dario Vinicio Guglietta
- Effect of ERAP1 modulation on induction of protective anti-tumour immunity
- University of Southampton - "Cancer Sciences Unit" Lab
ESR9: Paula Gragera Alvarez
- ERAP modulation as an innovative strategy for cancer treatment
- Ospedale Pediatrico Bambino Gesù. Roma, IT. - "Onco-haematology" Lab
ESR10: Kamila Król
- In vivo anti-tumour safety and efficacy of NK cell-based immunotherapeutic approach in preclinical models
- Ospedale Pediatrico Bambino Gesù. Roma, IT. - "Onco-haematology" Lab
ESR11: Sandra Llamas Rizo
- Design, synthesis and evaluation of phosphinic transition-state analogues of ERAP/IRAP
- National and Kapodistrian University of Athens, GR - "Organic Chemistry" Lab
ESR12: Aroosha Raja
- Molecular ecosystem of ERAP four distinct immune cell subsets from patients with ERAP-linked diseases
- University Medical Center Utrecht, NL - "BoerKuiper group"
ESR13: Adele Ponzoni
- Biomarkers discovery, compounds distribution, efficacy and toxicity analysis by Mass Spectrometry Imaging
- Imabiotech
ESR14: Filipa da Silva de Vasconcelos
- Development of drug delivery systems for ERAP/IRAP modulators
- Inocure
ESR15: Nikoletta Maria Koutroumpa
